CRS Clinical Research Services — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CRS is a leading European early-phase CRO with over 40 years of collective expertise, providing comprehensive clinical trial services from First-in-Human to Proof-of-Concept. It leverages a network of three specialized clinical units in Germany, offering tailored trial designs and deep therapeutic knowledge in metabolic, cardiovascular, and renal disorders. The company was recently acquired by hVIVO (January 2025), integrating it into a larger clinical research group and expanding its operational scale and reach.

EndocrinologyDermatologyCardiologyHematologyGastroenterologyNephrologyWomen’s HealthMetabolic Disorders

Technology Platform

Integrated network of three owned Clinical Pharmacology Units (CPUs) with >160 beds for early-phase trials, specializing in complex study designs (FIH, PoC, PK/PD, BE/BA, DDI, TQT) in metabolic, cardiovascular, renal, and other therapeutic areas.

Opportunities

The acquisition by hVIVO creates cross-selling opportunities, especially in infectious disease and vaccine development, combining challenge trials with clinical pharmacology.

Growing demand for complex early-phase studies for biologics and specialized therapies aligns perfectly with CRS's expertise and owned clinic infrastructure.

Risk Factors

Revenue is tied to client R&D spending cycles, creating susceptibility to biopharma budget cuts.

High competition in the CRO market pressures pricing and requires constant service differentiation.

Operational risks include trial delays and integration challenges following the hVIVO acquisition.

Competitive Landscape

CRS competes in the fragmented early-phase CRO market against large global players (IQVIA, LabCorp, Parexel) and numerous regional European specialists. Its differentiation lies in its owned German clinic network, deep therapeutic expertise in metabolic/cardiovascular areas, and, post-acquisition, its unique position within hVIVO's integrated service offering.

More companies in Digital Health & Biotech SaaS →More companies in Germany →